Navigation Links
Pharmion Corporation Announces 2007 Operating Results
Date:2/19/2008

/p>

December 31, December 31,

2007 2006 2007 2006

Net sales $71,466 $60,050 $267,300 $238,646

Operating expenses:

Cost of sales, inclusive of

royalties, exclusive of

product rights amortization 19,737 16,643 73,078 65,157

Research and development 30,377 19,951 102,369 70,145

Acquired in-process research - 54,283 8,000 78,763

Selling, general and

administrative 50,029 31,980 143,203 104,943

Product rights amortization 2,491 2,458 9,898 9,802

Total operating expenses 102,634 125,315 336,548 328,810

Operating loss (31,168) (65,265) (69,248) (90,164)

Interest and other income, net 3,716 1,640 10,164 6,926

Loss before taxes (27,452) (63,625) (59,084) (83,238)

Income tax expense 24 586 4,776 7,774

Net loss $(27,476) $(64,211) $(63,860) $(91,012)

Net loss per common share:

Basic and Diluted $(0.74) $(2.00) $(1.81) $(2.84)

Weighted average number of common

and common equivalent shares used to

calculate net loss per

common share:

Basic and Diluted 37,287 32,083 35,207 32,016

CONSOLIDATED BALANCE SHEET DATA

December 31, 2007 December 31, 2006

Cash, cash equivalents and

short-term investments $248,530 $136,213

Total assets 443,324 326,732

Total liabilities 84,379 53,650

Total stockhold
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmion Corporation to Announce Third Quarter 2007 Financial Results
2. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
3. Pharmion Corporation to Present at Bear Stearns 2007 Healthcare Conference
4. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
5. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
6. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
7. VLST Corporation Announces Board and Executive Management Appointments
8. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
9. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
10. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... to win races on the Formula 1 track could help ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based ... funded by healthcare provider Simplyhealth. Telemetry technology, which ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... -- Biostar Pharmaceuticals,Inc. ("Biostar" or the "Company") (OTC Bulletin Board: BSPM) today ... Highlights for Year Ended December 31, 2008:, ... from $15.9 million, for 2007., ... as compared to, $3,963,524 in 2007., ...
... Aerovance Inc. today announced that it has secured ... transactions since formation in 2004, the company has raised ... debt financing.This financing round, which consists of two tranches, ... the full pro rata participation of existing investors Apax ...
... will be holding its 22nd Annual Conference, May 4-7, 2009 at ... ... MN (PRWEB) April 7, 2009 -- The American Filtration and ... May 4-7, 2009 at the Sheraton Hotel in Bloomington Minnesota. ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 2Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 3Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 4Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 5Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 6Aerovance Secures $38 Million in Equity Financing 2Aerovance Secures $38 Million in Equity Financing 3University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference 2University of Minnesota Professor Dr. David Pui to Speak at American Filtration and Separation Society Conference 3
(Date:4/18/2014)... as soon as they,re planted may be good news for ... In the wild, a plant whose seeds sprouted at the ... than just an insurance policy against late frosts or unexpected ... advantages too: Plants whose seeds put off sprouting until ... in a team of researchers working at the National Evolutionary ...
(Date:4/17/2014)... densely forested and most densely populated quadrant of the ... values and practices. Disturbances associated with those needs, such ... have set the stage for management issues of considerable ... The report Five anthropogenic factors that will radically ... United States was published recently by the ...
(Date:4/17/2014)... for chili peppers. Information about archaeological remains of ancient ... the appearance of words for chili peppers in ancient ... and highlight the value of multi-proxy data analysis. Their ... nine papers presented in a special feature issue of ... on plant and animal domestication edited by Dolores ...
Breaking Biology News(10 mins):Plants with dormant seeds give rise to more species 2Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Chickens to chili peppers 2Chickens to chili peppers 3
... Toshisada Nishida is this year,s winner of the International ... research and contributions to primatology. The award was presented ... Scotland, on 7 August 2008. Nishida will also be ... ape and human evolution by the Leakey Foundation. He ...
... In a study on fetal alcohol syndrome, researchers were ... cells in a key area of the fetal brain ... acidic environment that alcohol produces. The cerebellum, the portion ... muscle coordination, is particularly vulnerable to injury from alcohol ...
... N.J., July 28 Ikaria Holdings, Inc., a ... the,U.S. Food and Drug Administration (FDA) has granted ... in the reduction of the incidence and,severity of ... organ,transplantation., Ralf Rosskamp, M.D., Executive Vice President ...
Cached Biology News:Springer editor Toshisada Nishida winner of 2 prestigious primatology awards 2Researchers block damage to fetal brain following maternal alcohol consumption 2Ikaria(R) Receives FDA Orphan Drug Designation for Inhaled Carbon Monoxide for Delayed Graft Function in Solid Organ Transplants 2